Cabometyx (cabozantinib) — United Healthcare

Initial criteria

• Diagnosis of one of the following: Stage IV or relapsed renal cell carcinoma (RCC) OR Hereditary leiomyomatosis and RCC (HLRCC)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Cabometyx therapy

Approval duration

12 months